Advanced Non-clear Cell Renal Cell Carcinoma
Conditions
Keywords
cancer, kidney cancer, sutent, everolimus, renal cancer, papillary renal cell, chromophobe renal cell, papillary, chromophobe
Brief summary
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
Detailed description
This will be an international (USA, Canada, and UK) open-label, outpatient, multicenter, randomized study of treatment with RAD001 (everolimus (Afinitor®) or sunitinib (Sutent®) in subjects with mRCC and non-clear cell histology. Special emphasis is placed on papillary and chromophobe histologies while sarcomatoid clear cell variants, medullary, and collecting duct carcinomas will be excluded (see eligibility). Subjects may continue receiving study drugs until disease progression, unacceptable toxicities, or withdrawal of consent, for a maximum of 24 months. Continuation of study assigned treatment will be allowed beyond 24 months at the discretion of the sponsor. Stratification variables will include histology (papillary vs. chromophobe) and Motzer risk criteria (0, 1-2, and 3). Tumor progression will be assessed locally and by independent review, in strict accordance with Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria measured every 12 weeks. At the time of progression, subjects will be taken off study other than simple administrative mortality follow-up. Primary pathologic samples and plasma/urine angiokine levels at baseline and over time will be collected and stored centrally for biomarker analysis.
Interventions
DRUGEverolimus
Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
DRUGSunitinib
50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
Sponsors
Novartis
Pfizer
Duke University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed advanced Renal Cell Carcinoma (RCC), with non-clear cell pathology. 2. RCC tumor tissue available for correlative sciences, from either primary or metastatic site or both. 3. At the time of screening, at least 4 weeks since prior palliative radiation therapy and/or major surgery, and resolution of all toxic effects of prior therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 4.0) Grade 1. 4. Subject must have radiographic evidence of metastatic disease with at least 1 measurable per RECIST 1.1 criteria (Attachment 1)\]. 5. Age \> 18 years. 6. Adequate laboratory values 7. Karnofsky Performance Status ≥ 60 (Attachment 2). 8. Life expectancy of at least 3 months. 9. Written, signed, dated, and witnessed Institutional Review Board (IRB) or Institutional Ethics Committee (IEC) approved informed consent form (ICF) before any screening procedures are performed.
Exclusion criteria
1. Subjects with a history of or active central nervous system (CNS) metastases. 2. Prior systemic therapy for RCC, including mTOR and anti-angiogenic therapy, chemotherapy, biologic or experimental therapy. 3. Subjects with collecting duct, medullary, small cell, oncocytoma, or lymphoma-type pathology. 4. Subjects receiving known strong CYP3A4 isoenzyme inhibitors and/or inducers. 5. Major surgery, open biopsy, traumatic injury, or radiotherapy within 4 weeks of the screening visit. 6. Subjects who have not recovered from prior biopsy, surgery, traumatic injury, and/or radiation therapy. 7. Presence of a non-healing wound or ulcer. 8. Grade 3 hemorrhage within the past month. 9. Hypertension with systolic blood pressure of \>180 mm Hg and/or diastolic pressure \>100 mm Hg. 10. Subjects with American Heart Association (AHA) Class 2-4 heart disease or any history of congestive heart failure with an ejection fraction \<50%, or history of unstable angina, myocardial infarction, coronary artery bypass graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism within 6 months of entry. 11. Diabetes mellitus with glycosylated hemoglobin A1c (HbgA1c) \> 10% despite therapy. 12. A history of interstitial pneumonitis. 13. Subjects with active autoimmune disorder(s) being treated with immunosuppressive agents within 4 weeks prior to the screening visit. 14. Subjects receiving immunosuppressive agents and those with chronic viral/bacterial/fungal illnesses such as human immunodeficiency virus (HIV). 15. Patients who have receive immunization with attenuated live vaccines within one week of study entry or during study period. 16. Patients with active infection(s), active antimicrobial therapy or serious intercurrent illness. 17. History of other prior malignancy in past 5 years. 18. Pregnant or nursing women. 19. Major medical/psychiatric illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in this study, including inability to absorb oral medications and history of noncompliance to medical regimens. 20. Known hypersensitivity to any of the components in everolimus or sunitinib product 21. Subjects taking agents that significantly prolong the QTc interval are not eligible. 22. Proteinuria with a spot urine protein/creatinine ratio \>2 or 24 hour urine protein \>2 grams per 24 hours. 23. Severely impaired lung function as defined as spirometry and Carbon Monoxide Diffusing Capacity (DLCO) that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air. 24. Advanced liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-tumor Activity as Measured by Median Progression Free Survival Time | 24 Months | The primary objective will be to compare the anti-tumor activity of everolimus and sunitinib in subjects with mRCC with non-clear cell pathology, as measured by progression-free survival (PFS) following treatment initiation according to RECIST 1.1 criteria. Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival Rates | 6, 12 and 24 months | 6-, 12-, and 24-month rates of PFS in each arm will be compared for each treatment arm. Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
| PFS Expressed in Months | 24 months | Progression-free survival (PFS) expressed in months as compared to an historic control (interferon-treated clear cell RCC control arm from the sunitinib phase III study). Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
| Overall Response Rate | 24 months | Defined as complete response \[CR\] and partial response \[PR\] by RECIST 1.1 criteria in each treatment arm.Overall Response Rate (ORR) = CR + PR. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
| Percentage of Participants With Stable Disease (SD) | Baseline to 36 months | Percentage of participants with stable disease during treatment is defined as stable disease \[SD\] by RECIST 1.1 criteria as calculated in each treatment arm. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| 12 Week Clinical Benefit Rate as Percentage | Baseline to 36 months | Rate of complete or partial response or stable disease by the RECIST 1.1 criteria lasting ≥ 12 weeks prior to progression. Benefit rate is defined as complete response \[CR\] and partial response \[PR\] and stable disease \[SD\] by RECIST 1.1 criteria in each treatment arm. Benefit rate = CR + PR + SD. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| Overall Survival Rates | 6, 12, 24, 36 months | To compare overall survival (OS) rates at 6, 12, 24, and 36 months and over time in each treatment arm. |
| Percentage of Participants With Adverse Events | 24 months | To assess toxicities associated with everolimus or sunitinib using NCI CTC version 4.0 criteria |
| Change in Quality-of-life | baseline, cycle 3 day 1 | To compare change in quality-of-life, as measured by the FACT-KSI scale at baseline and cycle 3 day 1 per subject in each treatment arm. Functional Assessment of Cancer Therapy Kidney Symptom Index. FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms. |
| Best Tumor Shrinkage as a Percentile in Each Arm | 24 months | To compare the best tumor shrinkage as a percentile in each treatment arm. The percentile change at each follow up visit is calculated by measuring the percentage change in the Sum of lesion measurement from baseline. The best tumor shrinkage is lowest percentile change. A decrease is indicated by a negative percentage. |
| Median Duration of Response (CR, PR, and SD) | 24 months | To compare the median duration of response (CR, PR, and SD) in each treatment arm. According to RECIST 1.1, Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| Median OS | Up to 40 months | To compare the median OS in each treatment arm. |
| Time-to-new Metastatic Disease in Each Treatment Arm | 36 months | To compare the time-to-new metastatic disease in each treatment arm, defined from the date of first study agent administration to the onset of a new evaluable site of disease, excluding the primary site and all sites documented at baseline |
Other
| Measure | Time frame | Description |
|---|---|---|
| Clinical Measures of Response and PFS With Baseline and Time-dependent Levels of Biomarkers | 36 months | To correlate clinical measures of response and PFS with baseline and time-dependent levels of biomarkers. These biomarkers include plasma angiokine levels, tissue immunohistochemical and genomic profiles, copy number as assessed by array-based comparative genomic hybridization (CGH), and known mutations in non-clear cell RCC |
| Changes in Copy Number, RNA Expression, and Immunohistochemical Profiles | 36 months | To evaluate in an exploratory fashion changes in copy number, RNA expression, and immunohistochemical profiles by microarray between primary non-clear cell RCC tumors and metastatic samples |
Countries
Canada, United Kingdom, United States
Participant flow
Recruitment details
131 participants signed consent. 22 were screen failures. 1 withdrew consent prior to being randomized. 108 participant were randomized.
Participants by arm
| Arm | Count |
|---|---|
| RAD001 Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
Everolimus: Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle. | 57 |
| Sunitinib Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
Sunitinib: 50 mg daily by mouth on days 1 through 28 of each 42 day cycle. | 51 |
| Total | 108 |
Baseline characteristics
| Characteristic | RAD001 | Sunitinib | Total |
|---|---|---|---|
| Age, Continuous | 61.9 years STANDARD_DEVIATION 11.85 | 60.9 years STANDARD_DEVIATION 15.3 | 61.4 years STANDARD_DEVIATION 13.53 |
| Sex: Female, Male Female | 13 Participants | 14 Participants | 27 Participants |
| Sex: Female, Male Male | 44 Participants | 37 Participants | 81 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 57 / 57 | 51 / 51 |
| serious Total, serious adverse events | 36 / 57 | 41 / 51 |
Outcome results
Primary
Anti-tumor Activity as Measured by Median Progression Free Survival Time
The primary objective will be to compare the anti-tumor activity of everolimus and sunitinib in subjects with mRCC with non-clear cell pathology, as measured by progression-free survival (PFS) following treatment initiation according to RECIST 1.1 criteria. Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Time frame: 24 Months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RAD001 | Anti-tumor Activity as Measured by Median Progression Free Survival Time | 5.6 Months |
| Sunitinib | Anti-tumor Activity as Measured by Median Progression Free Survival Time | 8.3 Months |
p-value: 0.157Log Rank
Secondary
12 Week Clinical Benefit Rate as Percentage
Rate of complete or partial response or stable disease by the RECIST 1.1 criteria lasting ≥ 12 weeks prior to progression. Benefit rate is defined as complete response \[CR\] and partial response \[PR\] and stable disease \[SD\] by RECIST 1.1 criteria in each treatment arm. Benefit rate = CR + PR + SD. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Baseline to 36 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| RAD001 | 12 Week Clinical Benefit Rate as Percentage | 24.6 percentage of particpants |
| Sunitinib | 12 Week Clinical Benefit Rate as Percentage | 41.2 percentage of particpants |
p-value: 0.066Chi-squared
Secondary
Best Tumor Shrinkage as a Percentile in Each Arm
To compare the best tumor shrinkage as a percentile in each treatment arm. The percentile change at each follow up visit is calculated by measuring the percentage change in the Sum of lesion measurement from baseline. The best tumor shrinkage is lowest percentile change. A decrease is indicated by a negative percentage.
Time frame: 24 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RAD001 | Best Tumor Shrinkage as a Percentile in Each Arm | -2.1 percentile decrease |
| Sunitinib | Best Tumor Shrinkage as a Percentile in Each Arm | -10.7 percentile decrease |
Secondary
Change in Quality-of-life
To compare change in quality-of-life, as measured by the FACT-KSI scale at baseline and cycle 3 day 1 per subject in each treatment arm. Functional Assessment of Cancer Therapy Kidney Symptom Index. FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms.
Time frame: baseline, cycle 3 day 1
Population: All participants who completed the cycle 3 day 1 visit.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| RAD001 | Change in Quality-of-life | -3.5 units on a scale | Standard Deviation 9.61 |
| Sunitinib | Change in Quality-of-life | -0.9 units on a scale | Standard Deviation 7.19 |
Secondary
Change in Quality-of-life
To compare change in quality-of-life, as measured by the FACT-KSI scale at baseline and end of treatment per subject in each treatment arm. Functional Assessment of Cancer Therapy Kidney Symptom Index. FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms.
Time frame: baseline, up to 40 months
Population: All participants who completed the End of treatment visit.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| RAD001 | Change in Quality-of-life | -6.6 units on a scale | Standard Deviation 7.83 |
| Sunitinib | Change in Quality-of-life | -6.4 units on a scale | Standard Deviation 10.04 |
Secondary
Change in Quality-of-life
To compare change in quality-of-life, as measured by the FACT-KSI scale at baseline and cycle 6 day1 per subject in each treatment arm. Functional Assessment of Cancer Therapy Kidney Symptom Index. FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms.
Time frame: baseline, cycle 6 day 1
Population: All participants who completed the cycle 6 day 1 visit.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| RAD001 | Change in Quality-of-life | -4.4 units on a scale | Standard Deviation 6.37 |
| Sunitinib | Change in Quality-of-life | -2.1 units on a scale | Standard Deviation 6.69 |
Secondary
Median Duration of Response (CR, PR, and SD)
To compare the median duration of response (CR, PR, and SD) in each treatment arm. According to RECIST 1.1, Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: 24 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RAD001 | Median Duration of Response (CR, PR, and SD) | 3.9 months |
| Sunitinib | Median Duration of Response (CR, PR, and SD) | 8.3 months |
Secondary
Median OS
To compare the median OS in each treatment arm.
Time frame: Up to 40 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RAD001 | Median OS | 13.2 months |
| Sunitinib | Median OS | 31.5 months |
Secondary
Overall Response Rate
Defined as complete response \[CR\] and partial response \[PR\] by RECIST 1.1 criteria in each treatment arm.Overall Response Rate (ORR) = CR + PR. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: 24 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| RAD001 | Overall Response Rate | 8.8 percentage of participants |
| Sunitinib | Overall Response Rate | 17.6 percentage of participants |
Secondary
Overall Survival Rates
To compare overall survival (OS) rates at 6, 12, 24, and 36 months and over time in each treatment arm.
Time frame: 6, 12, 24, 36 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| RAD001 | Overall Survival Rates | 6 months | 83.5 percentage probability |
| RAD001 | Overall Survival Rates | 12 months | 57.7 percentage probability |
| RAD001 | Overall Survival Rates | 24 months | 40.8 percentage probability |
| RAD001 | Overall Survival Rates | 36 months | 35.7 percentage probability |
| Sunitinib | Overall Survival Rates | 36 months | 46.2 percentage probability |
| Sunitinib | Overall Survival Rates | 6 months | 85.4 percentage probability |
| Sunitinib | Overall Survival Rates | 24 months | 51.3 percentage probability |
| Sunitinib | Overall Survival Rates | 12 months | 74.7 percentage probability |
Secondary
Percentage of Participants With Adverse Events
To assess toxicities associated with everolimus or sunitinib using NCI CTC version 4.0 criteria
Time frame: 24 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| RAD001 | Percentage of Participants With Adverse Events | 63.2 percentage of participants |
| Sunitinib | Percentage of Participants With Adverse Events | 80.4 percentage of participants |
Secondary
Percentage of Participants With Stable Disease (SD)
Percentage of participants with stable disease during treatment is defined as stable disease \[SD\] by RECIST 1.1 criteria as calculated in each treatment arm. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Baseline to 36 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| RAD001 | Percentage of Participants With Stable Disease (SD) | 59.6 percentage of participants |
| Sunitinib | Percentage of Participants With Stable Disease (SD) | 64.7 percentage of participants |
p-value: 0.589Chi-squared
Secondary
PFS Expressed in Months
Progression-free survival (PFS) expressed in months as compared to an historic control (interferon-treated clear cell RCC control arm from the sunitinib phase III study). Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Time frame: 24 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RAD001 | PFS Expressed in Months | 5.6 Months |
| Sunitinib | PFS Expressed in Months | 8.3 Months |
Comparison: A comparison of the median PFS for RAD001 arm was compared to the 95% confidence interval(CI) of the median PFS of the historical control (HC). The null hypothesis was that there is no difference in the median PFS between the treatment arms and the historical control. If the median PFS is outside the 95%CI for the HC,it is determined there is statistical evidence that median PFS is different from the HC.
Comparison: A comparison of the median PFS for Sunitinib arm was compared to the 95% confidence interval(CI) of the median PFS of the historical control (HC). The null hypothesis was that there is no difference in the median PFS between the treatment arms and the historical control. If the median PFS is outside the 95%CI for the HC,it is determined there is statistical evidence that median PFS is different from the HC.
Secondary
Progression Free Survival Rates
6-, 12-, and 24-month rates of PFS in each arm will be compared for each treatment arm. Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Time frame: 6, 12 and 24 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| RAD001 | Progression Free Survival Rates | 6 Months | 40.3 percentage of participants |
| RAD001 | Progression Free Survival Rates | 12 Months | 17.0 percentage of participants |
| RAD001 | Progression Free Survival Rates | 24 Months | 9.3 percentage of participants |
| Sunitinib | Progression Free Survival Rates | 6 Months | 55.0 percentage of participants |
| Sunitinib | Progression Free Survival Rates | 12 Months | 37.7 percentage of participants |
| Sunitinib | Progression Free Survival Rates | 24 Months | 22.8 percentage of participants |
Secondary
Time-to-new Metastatic Disease in Each Treatment Arm
To compare the time-to-new metastatic disease in each treatment arm, defined from the date of first study agent administration to the onset of a new evaluable site of disease, excluding the primary site and all sites documented at baseline
Time frame: 36 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RAD001 | Time-to-new Metastatic Disease in Each Treatment Arm | 19.4 months |
| Sunitinib | Time-to-new Metastatic Disease in Each Treatment Arm | 36 months |
Other Pre-specified
Changes in Copy Number, RNA Expression, and Immunohistochemical Profiles
To evaluate in an exploratory fashion changes in copy number, RNA expression, and immunohistochemical profiles by microarray between primary non-clear cell RCC tumors and metastatic samples
Time frame: 36 months
Other Pre-specified
Clinical Measures of Response and PFS With Baseline and Time-dependent Levels of Biomarkers
To correlate clinical measures of response and PFS with baseline and time-dependent levels of biomarkers. These biomarkers include plasma angiokine levels, tissue immunohistochemical and genomic profiles, copy number as assessed by array-based comparative genomic hybridization (CGH), and known mutations in non-clear cell RCC
Time frame: 36 months